About Sniper Sniper
Sniper Medical Technologies develops digital PCR platforms for research, translational and clinical laboratory workflows. Its VibroJet® architecture combines instrument development, assay experience and manufacturing capability; product uses depend on configuration and local authorization.
Our Mission
To provide accessible and precise diagnostic solutions for everyone.
Through platform-level innovation in digital PCR, Sniper aims to support more reliable molecular testing in clinical diagnostics, precision medicine and public health.
Making an Impact
From platform innovation to laboratory workflows
Sniper integrates proprietary technology, regulated product development, manufacturing capability and global collaboration to help laboratories adopt digital PCR in real-world diagnostic settings.
VibroJet®
Proprietary digital PCR technology
3 Sites
R&D and manufacturing presence in Suzhou, Beijing and Taicang
Global Reach
Regulatory and commercial milestones across major markets
Core Technology
VibroJet® Digital PCR Technology
At the core of Sniper’s platform is VibroJet®, a proprietary vibration-injection digital PCR technology. It supports automated droplet generation, absolute quantification and high-sensitivity detection, enabling digital PCR to be applied more efficiently in clinical molecular diagnostics.
Regulatory and Quality System
Built for clinical use and global compliance
Research and clinical applications
Digital PCR solutions for high-value molecular testing
Sniper’s digital PCR platform is designed to support demanding clinical applications, including:
- Hematologic malignancy monitoring
- Minimal residual disease monitoring
- Solid tumor liquid biopsy
- Complex infectious disease testing
By delivering precise and reproducible quantification, Sniper helps laboratories generate more confident molecular results for clinical decision-making.
Manufacturing and Supply Capability
From innovation to stable delivery
With R&D and manufacturing capabilities across Suzhou, Beijing and Taicang, Sniper has built an integrated system covering instrument development, reagent development, consumables, quality control, product registration and scaled manufacturing.
This end-to-end capability supports long-term cooperation with hospitals, laboratories, distributors and diagnostic partners.
This end-to-end capability supports long-term cooperation with hospitals, laboratories, distributors and diagnostic partners.
About Milestones
Selected milestones in Sniper’s technology, product and manufacturing development.
2018
Founded the company and initiated R&D of proprietary digital PCR technologies.2021
Entered clinical evaluation and was selected for the NMPA special procedure for innovative medical devices.2023
Received FDA clearance for the digital PCR platform and BCR-ABL1 (p210) %IS Kit (Digital PCR Method).2025
DQ24-Dx and BCR-ABL1 (p210) %IS Kit received NMPA Class III approval in China.2020
Completed the digital PCR prototype and secured angel-round financing.2022
Launched DQ24, the first fully automated digital PCR platform.2024
Initiated international collaborations and global reagent co-development programs.2026
Advance DQ24-Dx adoption across hematology, oncology, and infectious diseases.Work With Sniper
We welcome collaboration with clinical laboratories, hospitals, distributors, diagnostic companies, research institutions and strategic partners worldwide. Together, we can expand the clinical adoption of digital PCR and bring more precise molecular testing to real-world healthcare settings.
Talk to Our Team
Tell us about your laboratory, application area, or partnership interest, and our team will connect you with the right product or collaboration pathway.
You can also reach us directly at
- +86-512-62809514
- sniperorder@sniper-tech.com